Cargando…

A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark

BACKGROUND: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five...

Descripción completa

Detalles Bibliográficos
Autores principales: Hvelplund, Troels, Lange, Bibi, Bird, Susanne Djernes, Korsholm, Malene, Kjeldsen, Anette Drøhse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734368/
https://www.ncbi.nlm.nih.gov/pubmed/34991676
http://dx.doi.org/10.1186/s13023-021-02160-1
_version_ 1784628003627597824
author Hvelplund, Troels
Lange, Bibi
Bird, Susanne Djernes
Korsholm, Malene
Kjeldsen, Anette Drøhse
author_facet Hvelplund, Troels
Lange, Bibi
Bird, Susanne Djernes
Korsholm, Malene
Kjeldsen, Anette Drøhse
author_sort Hvelplund, Troels
collection PubMed
description BACKGROUND: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five outcome measures for HHT-patients to guide health care providers, some with limited experience in treating HHT, and thereby maximizing the number of HHT-patients receiving good care. The outcome measures cover the following aspects: (1) 90% of the patients should receive a pulmonary AVM (PAVM) screening; (2) 90% of the patients should receive written advice on nosebleed; (3) 70% should be assessed for iron deficiency; (4) 100% of the patients should receive written advice on antibiotic (AB) prophylaxis prior to dental and surgical procedures, and (5) 100% of relevant patients should receive written advice on pregnancy. We have introduced the outcome measures as Benchmarks in our HHT-centre and wanted to evaluate the extend of implementation we have achieved. We constantly struggle to secure the best possible treatment of our HHT-patients. METHODS: The study was a non-interventional retrospective study. Data was collected manually from patient records and from the Danish HHT-database. RESULTS: A total of 180 HHT-patients were included, all diagnosed in the period from January 1st, 2016, to December 31st, 2020. All patients were screened for PAVM. We could confirm that 66% of patients who had epistaxis received thoroughly advice. Assessment for iron deficiency was performed in 80% of the adult patients. Thoroughly advice on AB prophylaxis was documented in 75%. Thoroughly advice on pregnancy was documented in 80% of female patients 15–45 years of age. There were no significant differences over time for any of the outcome measures. CONCLUSIONS: The Danish HHT-centre reached the target threshold for outcome measures 1 and 3. It could not be documented that the target thresholds for outcome measures 2, 4, and 5 were achieved. As information and education are a very important part of HHT care, focus on and documentation that all patients receive the relevant advice must be a priority in order to ensure best care.
format Online
Article
Text
id pubmed-8734368
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87343682022-01-07 A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark Hvelplund, Troels Lange, Bibi Bird, Susanne Djernes Korsholm, Malene Kjeldsen, Anette Drøhse Orphanet J Rare Dis Research BACKGROUND: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five outcome measures for HHT-patients to guide health care providers, some with limited experience in treating HHT, and thereby maximizing the number of HHT-patients receiving good care. The outcome measures cover the following aspects: (1) 90% of the patients should receive a pulmonary AVM (PAVM) screening; (2) 90% of the patients should receive written advice on nosebleed; (3) 70% should be assessed for iron deficiency; (4) 100% of the patients should receive written advice on antibiotic (AB) prophylaxis prior to dental and surgical procedures, and (5) 100% of relevant patients should receive written advice on pregnancy. We have introduced the outcome measures as Benchmarks in our HHT-centre and wanted to evaluate the extend of implementation we have achieved. We constantly struggle to secure the best possible treatment of our HHT-patients. METHODS: The study was a non-interventional retrospective study. Data was collected manually from patient records and from the Danish HHT-database. RESULTS: A total of 180 HHT-patients were included, all diagnosed in the period from January 1st, 2016, to December 31st, 2020. All patients were screened for PAVM. We could confirm that 66% of patients who had epistaxis received thoroughly advice. Assessment for iron deficiency was performed in 80% of the adult patients. Thoroughly advice on AB prophylaxis was documented in 75%. Thoroughly advice on pregnancy was documented in 80% of female patients 15–45 years of age. There were no significant differences over time for any of the outcome measures. CONCLUSIONS: The Danish HHT-centre reached the target threshold for outcome measures 1 and 3. It could not be documented that the target thresholds for outcome measures 2, 4, and 5 were achieved. As information and education are a very important part of HHT care, focus on and documentation that all patients receive the relevant advice must be a priority in order to ensure best care. BioMed Central 2022-01-06 /pmc/articles/PMC8734368/ /pubmed/34991676 http://dx.doi.org/10.1186/s13023-021-02160-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hvelplund, Troels
Lange, Bibi
Bird, Susanne Djernes
Korsholm, Malene
Kjeldsen, Anette Drøhse
A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark
title A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark
title_full A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark
title_fullStr A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark
title_full_unstemmed A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark
title_short A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark
title_sort retrospective cohort study on european reference network for rare vascular diseases 5 outcome measures for hereditary haemorrhagic telangiectasia in denmark
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734368/
https://www.ncbi.nlm.nih.gov/pubmed/34991676
http://dx.doi.org/10.1186/s13023-021-02160-1
work_keys_str_mv AT hvelplundtroels aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT langebibi aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT birdsusannedjernes aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT korsholmmalene aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT kjeldsenanettedrøhse aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT hvelplundtroels retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT langebibi retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT birdsusannedjernes retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT korsholmmalene retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark
AT kjeldsenanettedrøhse retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark